Top

Published in:

01-06-2009 | Original Article

HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody

Authors: Wei Wang, Yasuhiko Nishioka, Shuji Ozaki, Ali Jalili, Shinji Abe, Soji Kakiuchi, Masatoshi Kishuku, Kazuo Minakuchi, Toshio Matsumoto, Saburo Sone

Published in: Cancer Immunology, Immunotherapy | Issue 6/2009

Abstract

HM1.24 antigen (CD317) was originally identified as a cell surface protein that is preferentially overexpressed on multiple myeloma cells. Immunotherapy using anti-HM1.24 antibody has been performed in patients with multiple myeloma as a phase I study. We examined the expression of HM1.24 antigen in lung cancer cells and the possibility of immunotherapy with anti-HM1.24 antibody which can induce antibody-dependent cellular cytotoxicity (ADCC). The expression of HM1.24 antigen in lung cancer cells was examined by flow cytometry as well as immunohistochemistry using anti-HM1.24 antibody. ADCC was evaluated using a 6-h ⁵¹Cr release assay. Effects of various cytokines on the expression of HM1.24 and the ADCC were examined. The antitumor activity of anti-HM1.24 antibody in vivo was examined in SCID mice. HM1.24 antigen was detected in 11 of 26 non-small cell lung cancer cell lines (42%) and four of seven (57%) of small cell lung cancer cells, and also expressed in the tissues of lung cancer. Anti-HM1.24 antibody effectively induced ADCC in HM1.24-positive lung cancer cells. Interferon-β and -γ increased the levels of HM1.24 antigen and the susceptibility of lung cancer cells to ADCC. Treatment with anti-HM1.24 antibody inhibited the growth of lung cancer cells expressing HM1.24 antigen in SCID mice. The combined therapy with IFN-β and anti-HM1.24 antibody showed the enhanced antitumor effects even in the delayed treatment schedule. HM1.24 antigen is a novel immunological target for the treatment of lung cancer with anti-HM1.24 antibody.

Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355:479–485PubMed

Spiro SG, Silvestri GA (2005) One hundred years of lung cancer. Am J Respir Crit Care Med 172:523–529PubMedCrossRef

Blackhall F, Ranson M, Thatcher N (2006) Where next for gefitinib in patients with lung cancer? Lancet Oncol 7:499–507PubMedCrossRef

Saijo N (2006) Recent trends in the treatment of advanced lung cancer. Cancer Sci 97:448–452PubMedCrossRef

Egri G, Takats A (2006) Monoclonal antibodies in the treatment of lung cancer. Eur J Surg Oncol 32:385–394PubMedCrossRef

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRef

Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne P, Bonomi P (2006) Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24:5253–5258PubMedCrossRef

Goto T, Kennel SJ, Abe M, Takishita M, Kosaka M, Solomon A, Saito S (1994) A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84:1922–1930PubMed

Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M, Hirano T, Tsuchiya M (1999) Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 258:583–591PubMedCrossRef

10.

Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, Inazawa J, Oritani K, Itoh M, Ochi T, Ishihara K, Hirano T (1995) Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26:527–534PubMedCrossRef

11.

Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T (1997) Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 90:3179–3186PubMed

12.

Jalili A, Ozaki S, Hara T, Shibata H, Hashimoto T, Abe M, Nishioka Y, Matsumoto T (2005) Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood 106:3538–3545PubMedCrossRef

13.

Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, Ho AD, Goldschmidt H et al (2006) Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol 34:486–496PubMedCrossRef

14.

Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden SL, Wang C, Teicher BA (2003) Identification of genes expressed in malignant cells that promote invasion. Cancer Res 63:8939–8947PubMed

15.

Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz H-D, Fichtner I (2005) Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 4:151–168PubMed

16.

Mitani K, Nishioka Y, Yamabe K, Ogawa H, Miki T, Yanagawa H, Sone S (2003) Soluble Fas in malignant pleural effusion and its expression in lung cancer cells. Cancer Sci 94:302–307PubMedCrossRef

17.

Nishioka Y, Yano S, Fujiki F, Mukaida N, Matsushima K, Tsuruo T, Sone S (1997) Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene trasduction: the possibility of immunological overcoming of multidrug resistance. Int J Cancer 71:170–177PubMedCrossRef

18.

Nishioka Y, Manabe K, Kishi J, Wang W, Inayama M, Azuma M, Sone S (2007) CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol 149:317–329PubMedCrossRef

19.

Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H (1999) Induction of systemic and therapeutic antitumor immunity using injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59:4035–4041PubMed

20.

Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Kawano T, Sone S (1998) Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer cells in NK-depleted SCID mice. Int J Cancer 78:480–485PubMedCrossRef

21.

Shrivastava P, Hanibuchi M, Yano S, Parajuli P, Tsuruo T, Sone S (1998) Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporine A or verapamil. Cancer Chemother Pharmacol 42:483–490PubMedCrossRef

22.

Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380–384PubMedCrossRef

23.

Weynants P, Lethe B, Brasseur F, Marchand M, Boon T (1994) Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer 56:826–829PubMedCrossRef

24.

Shichijo S, Hayashi A, Takamori S, Tsunosue R, Hoshino T, Sakata M, Kuramoto T, Oizumi K, Itoh K (1995) Detection of MAGE-4 protein in lung cancer. Int J Cancer 64:158–165PubMedCrossRef

25.

Wroblewski JM, Bixby DL, Borowski C, Yannelli JR (2001) Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer 33:181–194PubMedCrossRef

26.

Tajima K, Obata Y, Tamaki H, Yoshida M, Chen Y-T, Scanlan MJ, Old LJ, Kuwano H, Takahashi T, Takahashi T, Mitsudomi T (2003) Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 42:23–33PubMedCrossRef

27.

Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA (2002) Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung cancer. Cancer Res 62:3971–3979PubMed

28.

Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC (2002) Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression. Ann Surg 236:785–793PubMedCrossRef

29.

Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJG, Chen Y-T, Old LJ, Altorki NK (2005) Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11:8055–8062PubMedCrossRef

30.

Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nature 6:714–727

31.

Adams GP, Weiner LM (2005) Monoclonal antibody therapy of caner. Nature Biotechnol 23:1147–1157CrossRef

32.

Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y, Doi T, Shimotohno K, Harada T, Nishida E, Hayashi H, Sugano S (2003) Large-scale identification and characterization of human genes that activate NF-κB and MAPK signaling pathways. Oncogene 22:3307–3318PubMedCrossRef

33.

Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, Engel P (2005) Characterization of antibodies submitted to the B cell section of the 8th human leukocyte deifferentiation antigens workshop by flow cytometory and immunohistochemistry. Cell Immunol 236:6–16PubMedCrossRef

Title: HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
Authors: Wei Wang
Yasuhiko Nishioka
Shuji Ozaki
Ali Jalili
Shinji Abe
Soji Kakiuchi
Masatoshi Kishuku
Kazuo Minakuchi
Toshio Matsumoto
Saburo Sone
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0612-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

The immunosuppressive tumor microenvironment in hepatocellular carcinoma

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

Focal adhesion kinase as an immunotherapeutic target

Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study

Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer